|1.||Leprosy (Hansen's Disease)
|1.||Sarno, Euzenir N: 5 articles (10/2015 - 02/2010)|
|2.||Dogra, Sunil: 5 articles (06/2015 - 06/2005)|
|3.||Ramesh, V: 5 articles (01/2013 - 12/2000)|
|4.||Rao, D N: 4 articles (05/2015 - 11/2003)|
|5.||Khanna, Neena: 4 articles (05/2015 - 11/2003)|
|6.||Nath, Indira: 4 articles (01/2014 - 02/2012)|
|7.||Brennan, Patrick J: 4 articles (02/2013 - 06/2010)|
|8.||Narang, Tarun: 3 articles (06/2015 - 06/2005)|
|9.||Saini, Chaman: 3 articles (01/2014 - 01/2013)|
|10.||Spencer, John S: 3 articles (02/2013 - 06/2010)|
03/01/1990 - "A multidrug regimen effective against both new and relapsed cases of lepromatous leprosy, whether dapsone sensitive or dapsone resistant, is recommended for field use. "
03/01/1982 - "The nose in lepromatous leprosy; bacteriological and histopathological studies of patients treated with dapsone monotherapy for varying periods of time."
04/01/1969 - "An open trial of low doses of dapsone in the management of lepromatous leprosy."
07/01/1967 - "Analysis of a trial of dapsone vs placebo in lepromatous leprosy."
07/01/1965 - "2. Comparative trial of dapsone plus ditophal (Etisul) and dapsone alone in the treatment of lepromatous leprosy."
|2.||Immunoglobulin M (IgM)IBA
06/01/1995 - "The demonstration that the Rubino factor is an IgM now permits the identification of the epitope recognized by it, and this may be used as a tool to understand the specific cellular immune unresponsiveness which characterizes lepromatous leprosy."
01/01/1991 - "These results show that the immunological status of lepromatous leprosy can appear prior to clinical symptoms, and thus serology for anti-PGL-I IgM together with the Mitsuda test can be useful in an active search for new preclinical cases among high risk populations."
06/01/1990 - "The relationship between the duration of treatment and IgM antibody levels in lepromatous leprosy (LL) was studied. "
08/01/1985 - "An enzyme immunoassay titrating IgM antibody against phenolic glycolipid for diagnosis of lepromatous leprosy."
09/01/1984 - "In saliva, however, IgM was detected in only two cases with lepromatous leprosy and three tuberculoid cases. "
01/01/1989 - "Several new candidate vaccines against leprosy have been effective in breaking immunological unresponsiveness and engendering cell-mediated immunity in lepromatous leprosy patients, including the combination of BCG+ killed M. "
06/01/2005 - "Comparative evaluation of immunotherapeutic efficacy of BCG and mw vaccines in patients of borderline lepromatous and lepromatous leprosy."
08/01/1986 - "The results suggest that from an immunopathological standpoint experimental leprosy in mangabeys will provide a suitable model for the investigation of the pathogenesis of human lepromatous leprosy and for the evaluation of new antileprosy vaccines."
|4.||Rifampin (Rifampicin)FDA LinkGeneric
01/01/2013 - "This study reports an elderly patient who was diagnosed with rifampicin-resistant lepromatous leprosy. "
07/01/1982 - "Rifampicin (RFP) trial in lepromatous leprosy."
01/21/1978 - "Over 100 patients with lepromatous leprosy were treated with rifampicin in a series of pilot, uncontrolled, and controlled trials in 1968-77. "
12/01/1993 - "Loss of viability of Mycobacterium leprae isolated from nasal secretions of lepromatous leprosy patients following daily rifampicin and DDS therapy."
12/01/1992 - "During the decade between the mid 1970s and the mid-1980s, 12 rifampin (RMP)-containing combined regimens were tested among lepromatous leprosy patients in the Institut Marchoux. "
|5.||Clofazimine (Lamprene)FDA Link
10/01/1971 - "Efficacy of clofazimine in the prophylaxis and suppression of reactive phases of lepromatous leprosy."
04/01/2004 - "An autopsy study was done on a 45 year old female of lepromatous leprosy (LL) on MDT and long term high dosage of clofazimine. "
12/01/1992 - "Short-term trial of clofazimine in previously untreated lepromatous leprosy."
03/01/1976 - "A long term trial with clofazimine in reactive lepromatous leprosy."
01/01/1999 - "Clofazimine therapy for lepromatous leprosy: a historical perspective."
07/01/1972 - "Immunologic aspects of lepromatous leprosy with special reference to the study of antibodies."
11/01/1999 - "Addiction of anti-CD28 antibodies restores PBMC proliferation and IFN-gamma production in lepromatous leprosy patients."
01/01/1993 - "leprae in antigenicity to serum antibodies of lepromatous leprosy patients. "
12/15/1988 - "The gene for a 28-kDa Mycobacterium leprae protein Ag, a major target of antibodies from patients with lepromatous leprosy, was cloned from a lambda-gt11-M. "
05/01/1988 - "A patient with lepromatous leprosy and anticytoskeletal antibodies."
|7.||Immunoglobulin G (IgG)IBA
12/01/1999 - "While a significant fall in the level of IgG3 in ENL was observed as compared to lepromatous leprosy without ENL, higher levels of IgG1 and IgG2 were found in patients with reversal reactions compared to their active counterparts without reactions."
06/15/1992 - "The chromatography column was prepared with immunoglobulin G obtained from sera from patients with lepromatous leprosy. "
10/01/1991 - "High IgG responses were also found in some contacts of lepromatous leprosy patients. "
02/01/1990 - "The chromatography column was prepared with immunoglobulin G obtained from sera from patients with lepromatous leprosy. "
11/01/1989 - "A serum factor, believed to be an IgG autoantibody, in certain patients with lepromatous leprosy inhibits the proliferation of mitogen-stimulated lymphocytes. "
|8.||Levamisole (Decaris)FDA Link
02/01/1984 - "These results indicate that levamisole activates the macrophages which in turn results in an improved cell mediated immune response in lepromatous leprosy. "
07/01/1995 - "In this study the immunopotentiator levamisole as well as a mixture of BCG/Mycobacterium leprae were investigated in inactive lepromatous leprosy patients by using the Mitsuda reaction as a parameter. "
02/01/1984 - "In vitro studies on the effect of levamisole in lepromatous leprosy."
01/01/1983 - "Preliminary trial of intervention levamisole therapy in persistently bacteriologically positive lepromatous leprosy."
10/01/1986 - "Evaluation of levamisole, an immunopotentiator, in the treatment of lepromatous leprosy."
|9.||Thalidomide (Thalomid)FDA Link
09/01/2004 - "A few years after its withdrawal from the European and Canadian markets due to severe teratogenic effects, the unexpected activity of Thalidomide in reactive lepromatous leprosy stimulated further study. "
03/01/1992 - "In this study, thalidomide's effectiveness in halting chronic ENL and arresting a relapse into ENL was consistently associated with a decrease in the numbers of CD4+ lymphocytes in the blood of 2 male lepromatous leprosy patients."
06/01/2015 - "We present a case of a 29 year old man diagnosed as lepromatous leprosy with recurrent Type 2 reaction treated with thalidomide for 2 years. "
06/01/1987 - "We conclude that monocytes from patients with active lepromatous leprosy not receiving thalidomide have an intrinsic abnormality when assessed by chemotaxis."
06/01/1985 - "Three lepromatous leprosy patients with ENL had their T helper populations significantly increased after thalidomide therapy. "
03/01/1988 - "The administration of a vaccine containing ICRC bacilli, which is currently undergoing clinical trials in India, induces persistent lepromin conversion in lepromatous leprosy (LL) patients and lepromin-negative healthy subjects, with "upgrading" of tissue response in the former. "
11/01/2006 - "The diagnosis, based on clinical suspicion, is confirmed through bacteriological and histopathological analyses, as well as by means of the lepromin test (intradermal reaction that is usually negative in lepromatous leprosy form and positive in the tuberculoid form). "
09/01/2005 - "The finding of Mitsuda positivity in histopathologically proven polar lepromatous leprosy is extremely uncommon, and conversion of lepromin status following MDT has not so far been reported. "
06/01/2001 - "Vaccination induced lepromin conversion in 100% of lepromatous leprosy cases and lepromin negative household contacts and augmentation of lepromin reactivity in 100% of lepromin positive household contacts, which was stable for the 15 weeks duration of follow-up. "
01/01/1994 - "Slit-skin smears and histopathology from the lesions proved the diagnosis to be lepromatous leprosy with a bacterial index (BI) 6+. The initial lepromin test was negative. "
|1.||Drug Therapy (Chemotherapy)
03/01/1990 - "Chemotherapy trials in lepromatous leprosy using various combinations of existing antileprosy drugs were conducted jointly by Korea, The Philippines, and Thailand. "
03/01/1990 - "Joint chemotherapy trials in lepromatous leprosy conducted in Thailand, the Philippines, and Korea."
09/01/1978 - "Interrelationships among six patient characteristics recorded upon entry into the trial were analyzed for 67 patients with lepromatous and near-lepromatous leprosy admitted into two chemotherapy trials. "
09/01/1978 - "A statistical analysis of two chemotherapy trials in lepromatous leprosy. "
09/01/1978 - "A statistical analysis of two chemotherapy trials in lepromatous leprosy. "
06/01/2005 - "We describe an unusual case of occurrence of lichen scrofulosorum following BCG immunotherapy in a patient with lepromatous leprosy."
06/01/2005 - "Lichen scrofulosorum in a patient with lepromatous leprosy after BCG immunotherapy."
01/01/1994 - "Localized lepromatous leprosy and its response to chemo-immunotherapy."
09/01/1991 - "Immunotherapy with Mycobacterium w was given, in addition to standard multidrug therapy (MDT) to a lepromatous leprosy (LL) patient with a bacteriological index (BI) of 6. After 15 months of treatment this patient attained bacteriological negativity and clinical inactivity. "
01/01/1986 - "Attempts to overcome the defect in immunity of patients with lepromatous leprosy by immunoprophylaxis and immunotherapy are being investigated. "
03/01/2006 - "Only patients with lepromatous leprosy exhibited meaningful improvement in smell function after treatment. "
06/01/2009 - "We report a case of multiple relapses in a lepromatous leprosy patient after treatment with World Health Organisation (WHO) recommended multibacillary multidrug therapy (MBMDT). "
06/01/2015 - "We report a case of an old man with lepromatous leprosy diagnosed in 1983, treated with multidrug therapy until 1989 and presenting a leprosy relapse 15 years after treatment. "
06/01/2010 - "Erythema leprosum--after treatment of Lepromatous Leprosy."
07/01/1998 - "The individuals studied were: 5 borderline leprosy (BB) patients, 4 with a lepromatous leprosy (LL), all of whom were undergoing epidemiological surveillance after treatment and 44 household contacts: 21 of the LL and 23 contacts of the BB patients. "
12/01/2009 - "Surgical treatment of bilateral paralytic lagophthalmos using scapha graft in a case of lepromatous leprosy."
04/01/1971 - "Reversal effect of thymus grafts on lepromatous leprosy in thymectomized-irradiated mice."
07/01/1978 - "Reversal reaction in patients with lepromatous leprosy after transplantation of human fetal thymic grafts."
10/01/1986 - "A high incidence of positive results was also encountered in sera of patients with end-stage renal disease (30%), renal graft recipients (18%), and in patients with lymphoma or leukemia (44%), but interestingly enough, no positive tests were noted in patients with lepromatous leprosy."
|5.||Homologous Transplantation (Allograft)
01/01/1969 - "leprae, there is also a non-specific drop in the ability of patients with lepromatous leprosy to show other aspects of cell-mediated immune response, e.g., contact sensitivity and skin homograft rejection. "
01/01/1985 - "In agreement with previous studies, the NDVO antibodies are found in a wide variety of diseases in addition to IM, including Japanese IM-like syndrome (22%), syphilis (24%), lepromatous leprosy (30%), systemic lupus erythematosus (29%), multiple sclerosis (18%) and cancer (17%); these antibodies were also found in patients with renal allografts (29%). "